Organon & Co. Research and Development Expense
Organon & Co. (OGN) reported Research and Development Expense of $96.00 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-05-06
- Organon & Co. research and development expense for the quarter ending 2022-03-31 was $96.00M, a 43.28% increase year-over-year.
- Organon & Co. research and development expense for the quarter ending 2021-12-31 was $189.00M, a 215.00% increase year-over-year.
- Organon & Co. research and development expense for the quarter ending 2021-09-30 was $111.00M, a 105.56% increase year-over-year.
- Organon & Co. research and development expense for the quarter ending 2021-06-30 was $76.00M, a 49.02% increase year-over-year.
- Organon & Co. research and development expense for fiscal 2021 was $443.00M, a 110.95% increase from fiscal 2020.
- Organon & Co. research and development expense for fiscal 2020 was $210.00M, a 4.55% decline from fiscal 2019.
- Organon & Co. research and development expense for fiscal 2019 was $220.00M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $96.00M 10-Q · filed 2022-05-06 | $285.00M derived: sum of 2 quarters · filed 2022-05-06 | $396.00M derived: sum of 3 quarters · filed 2022-05-06 | $472.00M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | $189.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $300.00M derived: sum of 2 quarters · filed 2022-03-21 | $376.00M derived: sum of 3 quarters · filed 2022-03-21 | $443.00M 10-K · filed 2022-03-21 |
| 2021-09-30 | $111.00M 10-Q · filed 2021-11-12 | $187.00M derived: sum of 2 quarters · filed 2021-11-12 | $254.00M 10-Q · filed 2021-11-12 | $314.00M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-06-30 | $76.00M 10-Q · filed 2021-08-16 | $143.00M 10-Q · filed 2021-08-16 | $203.00M derived: sum of 3 quarters · filed 2022-05-06 | $257.00M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-03-31 | $67.00M 10-Q · filed 2022-05-06 | $127.00M derived: sum of 2 quarters · filed 2022-05-06 | $181.00M derived: sum of 3 quarters · filed 2022-05-06 | $232.00M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $114.00M derived: sum of 2 quarters · filed 2022-03-21 | $165.00M derived: sum of 3 quarters · filed 2022-03-21 | $210.00M 10-K · filed 2022-03-21 |
| 2020-09-30 | $54.00M 10-Q · filed 2021-11-12 | $105.00M derived: sum of 2 quarters · filed 2021-11-12 | $150.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $51.00M 10-Q · filed 2021-08-16 | $96.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $45.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $220.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |